TC Biopharm (TCBP) Competitors

TC Biopharm (NASDAQ:TCBP) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.

Is TCBP or TRVN more profitable?

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

Does the media favor TCBP or TRVN?

In the previous week, TC Biopharm had 1 more articles in the media than Trevena. MarketBeat recorded 2 mentions for TC Biopharm and 1 mentions for Trevena. TC Biopharm's average media sentiment score of 0.62 beat Trevena's score of 0.00 indicating that TC Biopharm is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TC Biopharm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, TCBP or TRVN?

TC Biopharm has higher revenue and earnings than Trevena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.06	-$7.35M	N/A	N/A
Trevena	$443K	2.44	-$40.29M	-$47.04	-0.03

Do analysts rate TCBP or TRVN?

TC Biopharm presently has a consensus target price of $48.00, indicating a potential upside of 6,948.46%. Trevena has a consensus target price of $5.00, indicating a potential upside of 300.00%. Given TC Biopharm's stronger consensus rating and higher probable upside, equities research analysts clearly believe TC Biopharm is more favorable than Trevena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Trevena	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do institutionals & insiders have more ownership in TCBP or TRVN?

16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer TCBP or TRVN?

Trevena received 614 more outperform votes than TC Biopharm when rated by MarketBeat users. Likewise, 68.75% of users gave Trevena an outperform vote while only 66.67% of users gave TC Biopharm an outperform vote.

Company	Underperform	Outperform
TC Biopharm	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%
Trevena	Outperform Votes 616 68.75%	Underperform Votes 280 31.25%

Which has more volatility and risk, TCBP or TRVN?

TC Biopharm has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Trevena has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Summary

TC Biopharm beats Trevena on 10 of the 14 factors compared between the two stocks.